NCT07459049 "Effect of Ibuprofen on Acute Inflammatory Response After One-Stage Periodontal Therapy"
| NCT ID | NCT07459049 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Baghdad |
| Condition | Periodontitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this ( Clinical Trial ) is to evaluate the efficacy of Ibuprofen in reducing acute inflammatory response (hs-CRP, ProCT, IL-6) after one hour and one week following one stage non surgical periodontal therapy. The main question it aims to answer is: "Does Ibuprofen effectively reduce the acute inflammatory response ( hs-CRP, ProCT, IL-6) following one-stage non-surgical periodontal therapy?"
Eligibility Criteria
Inclusion Criteria: 1. systemically healthy patients. 2. having a minimum of 20 teeth. 3. Generalized unstable periodontitis. 4. Pocket depth \[≥ 4 mm\]. 5. All included participants should be adults aged more than 18 years . 6. smokers and non smokers Exclusion Criteria: 1. Allergy or hypersensitivity to Ibuprofen or other NSAIDs. 2. current systemic anti-inflammatory or antibiotic therapy (\<3 months). 3. peptic ulcer disease. 4. recent periodontal therapy (\<3 months). 5. Asthma. 6. Renal impairment . 7. Hepatic impairment. 8. Severe cardiac disease (heart failure, hypertension (. 9. Bleeding disorders (e.g., hemophilia) or patients taking anticoagulants . 10. Any participant who had known or suspected high risk for tuberculosis, hepatitis B or HIV infections. 11. pregnant or lactating females. 12. those being unable to provide written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07459049 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Periodontitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07459049 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07459049 currently recruiting?
Yes, NCT07459049 is actively recruiting participants. Contact the research team at naba.ismail2405@codental.uobaghdad.edu.iq for enrollment information.
Where is the NCT07459049 trial being conducted?
This trial is being conducted at Baghdad, Iraq.
Who is sponsoring the NCT07459049 clinical trial?
NCT07459049 is sponsored by University of Baghdad. The trial plans to enroll 30 participants.